It is critically important that health care professionals screen for and diagnose Alzheimer’s disease (AD) in its early stages when symptoms are subtle and resemble normal aging, as brain changes may start years before symptoms manifest and the underlying pathology …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …
In recent years there has been an upsurge of new biologics and small-molecule therapies for ulcerative colitis (UC), making it challenging for the UC interdisciplinary care team (such as gastroenterologists, physician associates, and nurse practitioners) to stay abreast of these …
Current guidelines for antiretroviral therapy (ART) treatments for HIV do not necessarily include new treatment regimens for special populations such as those who are pregnant, have drug-resistant HIV, or comorbid conditions such as HBV. Health care practitioners (HCPs) therefore require …
Sickle cell disease (SCD) is a pathology caused by a mutative hemoglobin protein that produces rigid, sickle-shaped red blood cells (RBCs). Lifelong complications of SCD include acute veno-occlusive crises (VOCs), whose recurrence takes a significant toll on patients, and end-organ …
Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease. Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …
The Mycophenolate Pregnancy Registry was introduced to assess risks and outcomes associated with mycophenolate use during pregnancy – a situation that occurs far too often, despite boxed warnings and an ongoing REMS program.
In this second of two, interactive …
The Mycophenolate Risk Evaluation and Mitigation Strategy (MREMS) was initiated in 2012, yet more than a decade later prenatal exposure to mycophenolate, an immunosuppressive agent with significant teratogenicity, continues to occur at unacceptably high rates. While the MREMS provides direction …